May 10, 2018 06:31 AM EDT
R&D

Roche's big PhI­II Tecen­triq/Cotel­lic com­bo study for colon can­cer fails, dam­ag­ing Ex­elix­is shares

John Carroll

Editor & Founder

The Tecen­triq team at Roche/Genen­tech has run in­to an­oth­er nasty set­back. Their PD-L1 drug, com­bined with Cotel­lic, failed to make a sig­nif­i­cant dif­fer­ence on over­all …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times